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REAL-WORLD EPOETIN ALFA (EPO) AND DARBEPOETIN
ALFA (DARB) DOSING AND COST CONSIDERATIONS IN
ELDERLY HOSPITAL INPATIENTS: RESULTS FROM A LARGE
OBSERVATIONAL STUDY
Duh M1,Vekeman F2, Mckenzie RS3, Lefebvre P2, Watson S3,
Mody S3, Piech CT3
1Analysis Group, Inc, Boston, MA, USA, 2Groupe d’Analyse, Ltée,
Montréal, QC, Canada, 3Ortho Biotech Clinical Affairs, LLC,
Bridgewater, NJ, USA
OBJECTIVES: To examine inpatient dosing patterns and ery-
thropoietic treatment costs in cancer and pre-dialysis chronic
kidney disease (pCKD) elderly inpatients treated with erythro-
poietic agents from a hospital pharmacy perspective.
METHODS: Analysis of electronic inpatient records from the
Premier Perspective Database©, Premier Inc. Charlotte, NC, was
conducted. Subjects were identiﬁed through hospitalizations
recorded between 7/2002–3/2005 from >500 hospitals nation-
wide. Elderly patients (≥65 years) with an admitting diagnosis of
cancer or pCKD and receipt of EPO or DARB during hospital-
ization were included. Patients receiving dialysis or both agents
were excluded. For cancer and pCKD indications, baseline
demographics, severity of illness, inpatient length of stay, cumu-
lative administered dose, and drug costs were compared between
EPO and DARB patients. May 2006 wholesale acquisition costs
were used to calculate erythropoietic costs. RESULTS: A total of
13,940 hospitalizations (EPO:12,512; DARB:1428) for inpa-
tients with cancer and 42,856 (EPO:38,538; DARB:4318) for
inpatients with pCKD were identiﬁed. For both indications,
patient characteristics were comparable between the two groups.
Mean cumulative administered dose per inpatient stay (cancer:
EPO 59,529 +/− 48,182 Units, DARB 292 +/− 613 mcg; pCKD:
EPO 39,497 +/− 39,851 Units, DARB 184 +/− 348 mcg) resulted
in a dose ratio between EPO and DARB of 204 : 1 and 215 : 1
(Units EPO: mcg DARB) for cancer and pCKD inpatients,
respectively. Based on cumulative administered dose/hospitaliza-
tion, the price premium associated with DARB drug cost was
>70% when compared to EPO for both oncology and pCKD
inpatients (oncology: EPO $724 vs. DARB $1299 p < 0.0001;
pCKD: EPO $481 vs. DARB $818, p < 0.0001). CONCLU-
SION: Based on the evidence from this large retrospective analy-
sis of elderly inpatients, EPO was signiﬁcantly less costly
compared with DARB in both therapeutic areas. These results
are similar to those observed in elderly patients in the outpatient
setting with pCKD or cancer; and mirror results observed in
inpatients <65 years.
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FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR
NONSMALL CELL LUNG CANCER: PATTERNS OF CARE 
AND COST
Ramsey SD1, Martins R2, Blough DK3,Tock L1, Reyes C4, Lubeck D4
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Seattle
Cancer Care Alliance, Seattle, WA, USA, 3University of Washington,
Seattle, WA, USA, 4Genentech, Inc, South San Francisco, CA, USA
OBJECTIVES: The study objective is to characterize ﬁrst-,
second- and third-line chemotherapy use and costs for patients
with NSCLC from a payer’s perspective. METHODS: Enroll-
ment and claims records from a large, multistate private health
insurance plan were utilized to identify study subjects. Criteria
for analysis include subjects aged 21 years and older, with ≥3
ICD-9 diagnosis codes for NSCLC from January 2002 to Decem-
ber 2005 and continuous enrollment for 12 months prior to diag-
nosis. An algorithm was developed to identify ﬁrst-, second-, and
third-line agents based on chemotherapy (J-codes) sequencing
and delivery dates (CPT codes). Charge data were applied to esti-
mate costs. Direct medical care costs (inpatient, outpatient, phar-
macy, skilled nursing facility) were estimated over 12 and 24
months using the Kaplan-Meier Sample Average estimator to
account for deaths and disenrollments. RESULTS: A total of
42% of NSCLC cases received chemotherapy (n = 3323);
1860/3323 met criteria for analysis. Average age was 63 years
(range 26–103) and 44% were female. Most common therapies
(number of patients): ﬁrst-line: carboplatin + paclitaxel (939),
carboplatin + etoposide (321), carboplatin + gemcitabine (196),
carboplatin + docetaxel (185); second-line: docetaxel (98), geﬁ-
tinib (77), erlotinib (49), gemcitabine (37); third-line: geﬁtnib
(35), pemetrexed (14), erlotinib (13), carboplatin + paclitaxel
(13). Number starting treatment (%), mean observed treatment
time in months: ﬁrst-line only: 1332 (72%), 8; ﬁrst-/second-line:
375 (20%), 11; ﬁrst-/second-/third-line: 153 (8%), 14. Mean
costs (12 months): ﬁrst-line only: $136,385 (SE-2254); ﬁrst-/
second-line: $176,052 (SE-5040); ﬁrst-/second-/third-line:
$215,077 (SE-8215). Mean costs (24 months): ﬁrst-line only:
$153,752 (SE-3367); ﬁrst-/second-line: $213,528 (SE-7265);
ﬁrst-/second-/third-line: $277,007 (SE-12288). CONCLUSION:
Less than 1/3 of NSCLC patients receive second- and third-line
chemotherapy. Although treatment duration was longer for
patients receiving multiple lines of therapy, additional lines of
treatment did not signiﬁcantly increase average monthly costs
($19,500).
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IV THERAPIES IN METASTATIC BREAST CANCER PATIENTS IN
A US POPULATION
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1Wharton School, University of Pennsylvania, Philadelphia, PA, USA,
2GlaxoSmithKline, Collegeville, PA, USA, 3Medical Present Value,
Austin,TX, USA
OBJECTIVES: Trastuzumab, a monoclonal antibody, is admin-
istered intravenously as monotherapy or in combination with
chemotherapy in patients with metastatic breast cancer (MBC)
whose tumors over express HER2. This study assessed the cost
components of providing trastuzumab-based combination IV
therapies to women with MBC. METHODS: An administrative
claims database of >60 multi-specialty medical practices/clinics
in the US was used to identify women with MBC (ICD-9 code
174 including 196–198) between January 01, 2003 and May 31,
2006 and receiving trastuzumab plus another IV therapy. Allow-
able amounts for a claim, which closely represents the actual
payments to providers, were used to estimate costs cost per IV
administration visit. Billable cost components were categorized
based on published literature. RESULTS: A total of 151 patients
with 1292 clinic visits receiving any of 7 trastuzumab-based
combination IV therapies were identiﬁed. The total mean cost
per visit across all trastuzumab-based combinations was $3511
of which 70% was accounted for by drugs, 11% by adminis-
tration of the IV and 19% for other visit-related services, which
include supplies and equipment, evaluation and management ser-
vices, and other concomitantly administered IV or oral drugs.
Trastuzumab plus paclitaxel was the most commonly used com-
bination with non-drug costs accounting for 32% ($1072) of
total costs ($3341) per visit. The non-drug costs associated with
administration of the second most commonly used combination,
trastuzumab plus vinorelbine, were 24% ($612) of total costs
($2563) per visit. CONCLUSION: Excluding drug costs, costs
associated with IV administration of trastuzumab-based combi-
nation therapies and other visit-related services are approxi-
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mately 30% of total costs. Effective oral therapies for treatment
of breast cancer could help offset some of these costs in addition
to providing patient beneﬁts such as fewer clinic visits for IV
administration.
PCN28
A MARKOV MODEL EVALUATING THE COST-UTILITY OF A 
4D REAL-TIME ELECTROMAGNETIC TRACKING SYSTEM
(CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON
TRANSPONDERS) IN THE LOCALIZATION OF PROSTATE
TUMORS DURING RADIOTHERAPY
Williams E, Najib MM
AEQUITAS, San Diego, CA, USA
OBJECTIVES: Since accurate tumor localization during radio-
therapy is critical to maximizing therapeutic efﬁcacy while 
minimizing toxicity, the cost-effectiveness of localization tech-
nologies should be investigated. We performed a cost-utility
analysis evaluating the relative advantage of using a real-time 4D
electromagnetic tracking system, the Calypso® 4D Localization
System with Beacon® Transponders (“Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington) during
prostate radiotherapy. METHODS: Using decision analysis and
Markov processes, the outcomes of patients localized during
prostate radiotherapy were simulated over ﬁve years and mea-
sured as direct costs from a payer’s perspective and quality-
adjusted life years (QALYs). The clinical pathway for patients
undergoing external beam radiation was modeled via health
states: 1) Time in Treatment, 2) Relapse-Free with Localization,
3) Relapse-Free without Localization, and 4) Deceased. Using
evidence from a prospective clinical trial of the Calypso® 4D
Localization System and published literature, transition states
were modeled for achievement of biochemical no evidence of
disease (bNED) control and biochemical relapse-free survival
(BRFS). Costs and disutilities of radiation-induced toxicities
were included. Post-hoc sensitivity analyses were performed.
RESULTS: Over ﬁve years, patients localized with real-time 4D
electromagnetic tracking gained 2.47 QALYs at $5432/QALY.
Compared to ultrasound, electronic portal imaging devices, or
computed tomography, the real-time 4D electromagnetic track-
ing system yielded superior QALY gains at comparable costs.
Compared to ultrasound, this technology generated 43 addi-
tional quality-adjusted life days and an incremental cost-
effectiveness ratio of $14,053/QALY. Overall, the model was
sensitive to changes in bNED control rates and BRFS. CON-
CLUSION: The real-time 4D electromagnetic tracking system is
cost-effective for target localization during prostate radiother-
apy. However, the current model’s sensitivity to variances in
long-term outcomes warrants collection of rigorous evidence on 
long-term quality of life and tumor control in patients using
localization technologies. Future studies might incorporate
patient registry data, patient-reported outcomes, and follow-up
data from prospective clinical trials.
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A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE
TREATMENT OF METASTATIC RENAL CELL CARCINOMA 
IN MEXICO
Contreras-Hernandez I1, Mould-Quevedo J2, Salinas-Escudero G3,
Tapia-Valencia J2, Davila-Loaiza G2, Garduño-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Pﬁzer
Mexico, Mexico City, Mexico, 3Social Security Mexican Institute,
Mexico City, Federal District, Mexico
OBJECTIVES: Renal cancer represents 1.5% of all tumors
observed in Mexico and they are responsible of high expendi-
tures in the Mexican Health System. The purpose of the study
was to model the economic and health consequences of second-
line treatments (previous failure of cytokine therapies) in adult
patients with metastatic renal cell carcinoma (mRCC) in stages
III and IV from the health care payer’s perspective. METHODS:
A cost—utility analysis was developed using a Markov model-
ing approach. The model simulates costs and quality adjusted
life years (QALYs) gained in a ten-year period among four pos-
sible health states (no new progression, death due to mRCC,
history of new progression and death due to other causes). The
model aimed to compare sunitinib 50 mg/day vs. local best sup-
portive care (BSC) as second-line treatments. Transition prob-
abilities and QALYs of the Markov model were obtained
according to clinical trials previously published in the literature.
Resource use and costs data was obtained from hospital records
at Hospital de Oncología CMN “Siglo XXI” in Mexico City (n
= 80). Both costs and QALYs were discounted using a 5% annual
rate. Probabilistic sensitivity analysis was performed and
tornado diagrams were constructed (±25% on relevant model
variables). RESULTS: Second line treatment with sunitinib
showed the highest QALYs gained per patient (1.32 QALYs) vs.
BSC treatment (0.39 QALYs). Nevertheless, expected health care
costs for sunitinib resulted in US$36,928 and BSC therapies in
US$4103. The incremental cost per QALY gained resulted in
US$35,238. Results were robust to Monte Carlo ﬁrst order sen-
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